Skip to main content

Advertisement

Springer Nature Link
Log in

Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database

  • Published:
Journal of Racial and Ethnic Health Disparities Aims and scope Submit manuscript

Abstract

Background

Gastrointestinal tumors (GISTs) represent the most common mesenchymal tumors of the gastrointestinal tract. There has been limited data on GIST incidence and survival disparities between ethnic groups.

Aims

Assess disparities in incidence and survival among race in the USA in the era of available GIST histologic codes and treatment.

Methods

We queried Surveillance, Epidemiology, and End Results (SEER) database for GIST from 2002 to 2015, with diagnostic code 8936.

Results

Of the 7204 patients identified, 4928 (68.4%) were White, 1308 (18.2%) African American (AA), and 968 (13.4%) were classified as “Other” (American Indian/Alaskan Native, Asian/Pacific Islander). The overall incidence rate (IR) was 0.75 per 100,000. IR was highest among AA at 1.37/100,000, but 0.65/100,000 for Whites, 1.10/100,000 for Asians/Pacific Islanders, and 0.28/100,000 for American Indians/Alaskan Natives. The GIST incidence was twice as high for AA as for Whites (rate ratio [RR]: 2.12; 95% CI: 1.98–2.26; p < 0.001). There was higher proportion of Whites than AA, who underwent surgical extirpation. Median overall survival (OS) and GIST specific survival (GSS) were not reached for all race, which indicates more than half of the patients were still alive at end of follow-up period. In multivariate Cox model, belonging to “Other” had better OS (adjusted hazard ratio [aHR]; 0.73, 95% CI: 0.55–0.95, P = 0.021) for GIST, but no difference in prognosis and OS for AA and White [(aHR for whites; 0.84, 95% CI: 0.69–1.02, P = 0.071), AA = reference]. There was no difference in GSS among races.

Conclusions

Significant racial disparity in incidence and overall survival for GIST exists, and efforts should be made to bridge this gap and improve outcomes for all races. The overall incidence rate for GIST was noted to be 7.5 per 1 million, and IR of GIST was twice as high for African Americans as compared to Whites. The “Other” racial group (American Indians/Alaskan Natives, Asians, and Pacific Islanders) had superior OS as compared to African Americans and Whites.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202(4):623–9.

    Article  PubMed  Google Scholar 

  2. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100(1):162–8.

    Article  PubMed  Google Scholar 

  3. Blanke C, Eisenberg BL, Heinrich M. Epidemiology of GIST. Am J Gastroenterol. 2005;100(10):2366.

    Article  PubMed  Google Scholar 

  4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.

    Article  CAS  PubMed  Google Scholar 

  5. Khanna A, et al. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 2006;10(5):689–97.

    Article  PubMed  Google Scholar 

  6. DeMatteo RP, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cheung MC, Zhuge Y, Yang R, Koniaris LG. Disappearance of racial disparities in gastrointestinal stromal tumor outcomes. J Am Coll Surg. 2009;209(1):7–16.

    Article  PubMed  Google Scholar 

  8. Day JC. Population projections of the United States, by age, sex, race, and Hispanic origin: 1992 to 2050. Bureau: US Department of Commerce, Economics and Statistics Administration; 1992.

    Google Scholar 

  9. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547–69.

    Article  PubMed  Google Scholar 

  10. Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Prev Biomarkers. 2015;24(1):298–302.

    Article  Google Scholar 

  11. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68.

    Article  PubMed  Google Scholar 

  12. de Raedt T, Cools J, Debiec–Rychter M, Brems H, Mentens N, Sciot R, et al. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology. 2006;131(6):1907–12.

    Article  CAS  PubMed  Google Scholar 

  13. Fletcher CD, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10(2):81–9.

    Article  PubMed  Google Scholar 

  14. Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag. 2008;4(1):149–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. 2005;103(4):821–9.

    Article  PubMed  Google Scholar 

  16. Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117(2):289–93.

    Article  CAS  PubMed  Google Scholar 

  17. Leoncini E, Carioli G, la Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):68–81.

    Article  CAS  PubMed  Google Scholar 

  18. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–6.

    Article  PubMed  Google Scholar 

  19. Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial disparity in gastrointestinal Cancer risk. Gastroenterology. 2017;153(4):910–23.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kawanowa K, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37(12):1527–35.

    Article  PubMed  Google Scholar 

  21. Dong E, Duan L, Wu BU. Racial and ethnic minorities at increased risk for gastric Cancer in a regional US population study. Clin Gastroenterol Hepatol. 2017;15(4):511–7.

    Article  PubMed  Google Scholar 

  22. Nguyen T, Ramsey D, Graham D, Shaib Y, Shiota S, Velez M, et al. The prevalence of helicobacter pylori remains high in African American and Hispanic veterans. Helicobacter. 2015;20(4):305–15.

    Article  PubMed  Google Scholar 

  23. Li K, et al. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget. 2017;8(36):60589–604.

    PubMed  PubMed Central  Google Scholar 

  24. Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, et al. Gastric and small intestine gastrointestinal stromal tumors: do outcomes differ? J Surg Oncol. 2017;115(3):351–7.

    Article  CAS  PubMed  Google Scholar 

  25. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.

    Article  PubMed  Google Scholar 

  26. Bolen JC, et al. State-specific prevalence of selected health behaviors, by race and ethnicity--behavioral risk factor surveillance system, 1997. MMWR CDC Surveill Summ. 2000;49(2):1–60.

    CAS  PubMed  Google Scholar 

  27. Freeman HP. Poverty, culture, and social injustice: determinants of cancer disparities. CA Cancer J Clin. 2004;54(2):72–7.

    Article  PubMed  Google Scholar 

  28. Henschke UK, Leffall LD, Mason CH, Reinhold AW, Schneider RL, White JE. Alarming increase of the cancer mortality in the U.S. black population (1950-1967). Cancer. 1973;31(4):763–8.

    Article  CAS  PubMed  Google Scholar 

  29. Nikfarjam M, Kimchi E, Shereef S, Gusani NJ, Jiang Y, Liang J, et al. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg. 2008;12(11):2023–31.

    Article  PubMed  Google Scholar 

  30. Geiger HJ. Racial and ethnic disparities in diagnosis and treatment: a review of the evidence and a consideration of causes. Unequal Treat. 2003;417.

  31. Dimick J, Ruhter J, Sarrazin MV, Birkmeyer JD. Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. Health Aff (Millwood). 2013;32(6):1046–53.

    Article  Google Scholar 

  32. Haider AH, et al. Racial disparities in surgical care and outcomes in the United States: a comprehensive review of patient, provider, and systemic factors. J Am Coll Surg. 2013;216(3):482–92 e12.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Rubin JL, Sanon M, Taylor DC, Coombs J, Bollu V, Sirulnik L. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med. 2011;4:121–30.

    PubMed  PubMed Central  Google Scholar 

  34. Ng EH, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215(1):68–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Joensuu H, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2015;34(3):244–50.

    Article  CAS  PubMed  Google Scholar 

  37. Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010;363(6):596–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are thankful to Paschal Apanga (University of Nevada, Reno) for his help and suggestions.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA

    Mark B. Ulanja, Mohit Rishi, Bryce D. Beutler, Santhosh Ambika & Nageshwara Gullapalli

  2. College of Arts and Sciences, Vanderbilt University, Kirkland Hall, 2201 West End Ave., Nashville, TN, 37235, USA

    Kenneth G. Konam

  3. Renown Institute for Cancer, 1155 Mill St., Reno, NV, 89502, USA

    Santhosh Ambika

  4. VA Sierra Nevada Health Care System, 975 Kirman Ave., Reno, NV, 89502, USA

    Tomas Hinojosa

  5. Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA

    Francis T. Djankpa

  6. Center for Surveys, Evaluation and Statistics, School of Community Health Sciences, University of Nevada, Reno, 1664 N. Virginia St., Reno, NV, 89557, USA

    Wei Yang

Authors
  1. Mark B. Ulanja
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Mohit Rishi
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Bryce D. Beutler
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Kenneth G. Konam
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Santhosh Ambika
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Tomas Hinojosa
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Francis T. Djankpa
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Wei Yang
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Nageshwara Gullapalli
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

MBU, MR, BDB, TH, and GN conceived the idea and prepared manuscript. MR, KGK, MBU drafted the initial manuscript. MBU performed the computations. WY helped with computation and statistical analysis. TD helped with manuscript writing. SA, NG, TH guided the preparation process and writing of the manuscript. All authors read and approved of the manuscript prior to publication.

Corresponding author

Correspondence to Mark B. Ulanja.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

There was no IRB approval needed for this research, as it utilizes public, de-identified data.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ulanja, M.B., Rishi, M., Beutler, B.D. et al. Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database. J. Racial and Ethnic Health Disparities 6, 1035–1043 (2019). https://doi.org/10.1007/s40615-019-00605-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40615-019-00605-9

Keywords